Promising single-agent efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib supports the notion that BCR signaling is essential in the pathogenesis of ABC DLBCL and MCL [8, 9]. This evidence concerns the gene BCR and aneurysmal bone cyst.